STUDIES OF PHOTOTHERAPY AND FREE RADICAL LYMPHOKINE RELATIONSHIPS

我们的实验室继续研究光动力疗法， 恶性肿瘤的治疗 我们已经证明， 针对弱致敏剂的单克隆抗体将提高特异性， 以及在光动力疗法的体内模型中的长期治愈。 我们继续在人体试验中进行调查，以确定最大的 用于胸膜内递送的耐受剂量的光疗。 截至2009年6月， 1992年，42名患者进入胸膜内光动力学检查 在三名患者的队列中进行的轻剂量递增的治疗试验。 我们已经公布了通过这些来监测光线的能力 治疗。 我们已经证明，最大耐受剂量的 术中胸膜光动力疗法是30焦耳/平方厘米， 在24小时给药2 mg/kg Photofrin II后光照。 我们找到了 次高剂量的光疗光（32.5焦耳/平方厘米） 导致了食道并发症 我们还调查了使用 一些新的化合物，以防止肿瘤坏死因子的毒性。 发现钾通道激活剂尼可地尔降低了 巨噬细胞从LPS刺激产生TNF可能是通过 呼吸爆发减少。 此外，还发现了硝酮PBN， 通过下调血清中LPS的浓度， 产生肿瘤坏死因子。 其他化合物的研究 其可用于保护免受细胞因子毒性， 在体外和体内模型中继续我们的部分。

Our laboratory has continued investigation of photodynamic therapy for the treatment of malignancy. We have shown that conjugation of monoclonal antibody to a weak sensitizer will improve the specificity as well as the long-term cures in an in vivo model of photodynamic therapy. We continue with investigations in human trials to establish the maximum tolerated dose of phototherapy for intrapleural delivery. As of June of 1992 42 patients have been entered on an intrapleural photodynamic therapy trial with light dose escalation in cohorts of three patients. We have published the ability to monitor the light through these treatments. We have shown that the maximum tolerated dose of intraoperative pleural photodynamic therapy is 30 Joules/cm-squared of light after a 24 hour dosing of 2 mg/kg of Photofrin II. We found the next highest dose of phototherapy light (32.5 Joules/cm-squared) resulted in esophageal complications. We have also investigated use of a number of novel compounds to prevent tumor necrosis factor toxicity. Potassium channel activator, Nicorandil, was found to decrease macrophage TNF production from an LPS challenge possibly through a reduction in respiratory burst. Moreover, the nitron PBN was found to abrogate the lethality of LPS in vivo through down regulation of serum production of tumor necrosis factor. Investigations of other compounds which may be useful in protecting against cytokine toxicity is continuing in our section within in vitro and in vivo models.